Robert Chen and his team like strategies like direct indexing because they systematically tax loss harvest throughout the ...
"Everybody knows you made a mistake. How are you going to deal with that?" ...
Morgan Stanley upgraded Vir Biotechnology (NASDAQ:VIR) to Overweight from Equal Weight on Thursday after the cancer drug ...
While Citi, BofA and Goldman touted their biggest cohorts of managing directors in years, Morgan Stanley elevated greater ...
JP Morgan analyst Kian Abouhossein maintained a Neutral rating and boosted the price target from $100 to $104 on Dec. 6, 2024 ...
Morgan Stanley is a buy on weakness with strong dividend growth and projected revenue growth in Q4 2024 and early 2025. Click for our MS earnings preview.
Oklahoma-based financial advisors John “David” Veitch and his son Drew are joining Raymond James’ employee advisor channel, ...
Morgan Stanley initiated coverage of Palantir Technologies Inc. (NYSE:PLTR) with an underweight rating and $60 price target ...
Morgan Stanley closed $8.38 short of its 52-week high ($136.24), which the company achieved on November 25th.
Jim Caron of Morgan Stanley Investment Management explains what's behind the steepening yield curve and what it's telling us ...